Prostate Cancer

... Therapeutics Daily username : password : Remember me Newsletter Overviews Infectious Disease Article Preview U.S.

patent issued to Arius Research for anti-CD63 antibody for cancer treatment Women's Health Weekly - Apr.

06, 2006 Arius Research Inc.

(ARI) announced that it has received notice from the United States Patent and Trademark Office that U.S.

patent No.

7,009,040 was issued for Arius' lead anti-CD63 antibody, AR7BD-33-11A to treat cancer.

Previously Arius announced that it had received a Notice of Allowance in October 2005.

The patent covers the antibody molecule, various uses of the antibody, its derivatives, and a method for using it, and other similar antibodies, to treat cancers such as prostate and breast cancer.

Arius has several additional patent applications pending that will continue to enhance the value of this and other important ...

To continue reading the complete article, login or register below and get free instant access.

The complete article is 185 words long.

Login to Your Account Already have a TherapeuticsDaily.com or PharmaLive.com account?

Click on the button below to login.

Login to Your Account username : password : Remember me Free Access with Registration Access to TherapeuticsDaily.com is free for registered users.

To start the registration process, enter the fields below.

Email Zip Code Paid Advertiseme...

Read more...